While the maintenance of an Outperform rating suggests Baird's continued confidence in Calidi Biotherapeutics' potential, the significant reduction in the price target could indicate concerns about near-term challenges or revised expectations for the company's growth prospects. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the implications.